Sera PrognosticsSERA
About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Employees: 64
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
0.04% less ownership
Funds ownership: 55.17% [Q4 2024] → 55.13% (-0.04%) [Q1 2025]
3% less funds holding
Funds holding: 73 [Q4 2024] → 71 (-2) [Q1 2025]
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
49% less capital invested
Capital invested by funds: $147M [Q4 2024] → $74.4M (-$72.8M) [Q1 2025]
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
Research analyst outlook
We haven’t received any recent analyst ratings for SERA.
Financial journalist opinion









